vascular endothelial growth factors

Summary

Summary: A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.

Top Publications

  1. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
  2. ncbi Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 380:435-9. 1996
  3. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
  4. pmc Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    G Bergers
    Department of Biochemistry and Biophysics, University of California, 513 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Cell Biol 2:737-44. 2000
  5. ncbi Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
    J Holash
    Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Science 284:1994-8. 1999
  6. ncbi Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nature 380:439-42. 1996
  7. ncbi Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
    G Thurston
    Department of Anatomy and Cardiovascular Research Institute, University of California, San Francisco, CA 94143 0452, USA
    Science 286:2511-4. 1999
  8. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
  9. pmc Vascular endothelial growth factors and vascular permeability
    David O Bates
    Microvascular Research Laboratories, Department of Physiology and Pharmacology, School of Veterinary Sciences, Bristol Heart Institute, University of Bristol, Southwell Street, Bristol, UK
    Cardiovasc Res 87:262-71. 2010
  10. ncbi Molecular and biological properties of vascular endothelial growth factor
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 77:527-43. 1999

Research Grants

  1. Role of a9b1 Integrin in lymphangiogenesis
    Nicholas Vlahakis; Fiscal Year: 2007
  2. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2007
  3. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2009
  4. Vascular endothelial growth factor induced lung edema
    Robert Kaner; Fiscal Year: 2004
  5. A Novel Model to Study Retinopathy of Prematurity
    David Moscatelli; Fiscal Year: 2003
  6. Augmentation of Lymphangiogenesis by Increased Fluid Channeling in Mouse Skin
    Jeremy Goldman; Fiscal Year: 2007
  7. VEGFs in tumor lymphatic metastasis
    HAROLD FISHER DVORAK; Fiscal Year: 2010
  8. THE MAJOR ANGIOGENIC FACTORS IN PLACENTAL ANGIOGENESIS
    Lawrence Reynolds; Fiscal Year: 2004
  9. Integrins and bone matrix in prostate cancer
    Tatiana Byzova; Fiscal Year: 2003
  10. Integrins and bone matrix in prostate cancer
    Tatiana Byzova; Fiscal Year: 2006

Detail Information

Publications254 found, 100 shown here

  1. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
    ..This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed...
  2. ncbi Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 380:435-9. 1996
    ....
  3. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
    ..VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration...
  4. pmc Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    G Bergers
    Department of Biochemistry and Biophysics, University of California, 513 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Cell Biol 2:737-44. 2000
    ..Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch...
  5. ncbi Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
    J Holash
    Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Science 284:1994-8. 1999
    ....
  6. ncbi Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nature 380:439-42. 1996
    ..Angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Furthermore, VEGF-null embryonic stem cells exhibit a dramatically reduced ability to form tumours in nude mice...
  7. ncbi Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
    G Thurston
    Department of Anatomy and Cardiovascular Research Institute, University of California, San Francisco, CA 94143 0452, USA
    Science 286:2511-4. 1999
    ..Ang1 therefore may be useful for reducing microvascular leakage in diseases in which the leakage results from chronic inflammation or elevated VEGF and, in combination with VEGF, for promoting growth of nonleaky vessels...
  8. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  9. pmc Vascular endothelial growth factors and vascular permeability
    David O Bates
    Microvascular Research Laboratories, Department of Physiology and Pharmacology, School of Veterinary Sciences, Bristol Heart Institute, University of Bristol, Southwell Street, Bristol, UK
    Cardiovasc Res 87:262-71. 2010
    b>Vascular endothelial growth factors (VEGFs) are key regulators of permeability. The principal evidence behind how they increase vascular permeability in vivo and in vitro and the consequences of that increase are addressed here...
  10. ncbi Molecular and biological properties of vascular endothelial growth factor
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 77:527-43. 1999
    ..Currently, both therapeutic angiogenesis using recombinant VEGF or VEGF gene transfer and inhibition of VEGF-mediated pathological angiogenesis are being pursued...
  11. ncbi Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells
    I Kim
    National Creative Research Initiatives Center for Cardiac Regeneration, and the Department of Urology, Chonbuk National University School of Medicine, Chonju, 560-180, Republic of Korea
    J Biol Chem 276:7614-20. 2001
    ..The existence of parallel inverse signaling implies that the induction of adhesion molecule expression by VEGF is very finely regulated...
  12. ncbi Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics
    H Zhong
    The Johns Hopkins Oncology Center, Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Res 60:1541-5. 2000
    ..These data indicate that pharmacological agents that target PI3K, AKT, or FRAP in tumor cells inhibit HIF-1alpha expression and that such inhibition may contribute to therapeutic efficacy...
  13. ncbi Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
    B Oosthuyse
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, B 3000, Belgium
    Nat Genet 28:131-8. 2001
    ..Acute ischemia is known to cause nonselective neuronal death. Our results indicate that chronic vascular insufficiency and, possibly, insufficient Vegf-dependent neuroprotection lead to the select degeneration of motor neurons...
  14. ncbi Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor
    M Sondell
    Department of Animal Physiology, Lund University, Helgonav 3 B, S 223 62, Lund, Sweden
    Eur J Neurosci 12:4243-54. 2000
    ..The results strongly suggest that VEGF acts as a neurotrophic factor and plays an important role during the regeneration of peripheral nerves...
  15. ncbi Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development
    Chenghua Gu
    Department of Neuroscience, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA
    Dev Cell 5:45-57. 2003
    ..multiple ligands from structurally distinct families, including secreted semaphorins (Sema) and vascular endothelial growth factors (VEGF)...
  16. doi How do angiopoietins Tie in with vascular endothelial growth factors?
    Pipsa Saharinen
    Molecular and Cancer Biology Program, Biomedicum Helsinki, University of Helsinki, Finland
    Curr Opin Hematol 17:198-205. 2010
    ....
  17. ncbi VEGF is required for growth and survival in neonatal mice
    H P Gerber
    Departments of Cardiovascular Research and Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Development 126:1149-59. 1999
    ..Thus, VEGF is essential for growth and survival in early postnatal life. However, in the fully developed animal, VEGF is likely to be involved primarily in active angiogenesis processes such as corpus luteum development...
  18. ncbi Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
    H P Gerber
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 273:30336-43. 1998
    ..Inhibition of apoptosis may represent a major aspect of the regulatory activity of VEGF on the vascular endothelium...
  19. doi Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer
    Sònia Tugues
    Uppsala University, Dept of Immunology, Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjoldsv 20, 751 85 Uppsala, Sweden
    Mol Aspects Med 32:88-111. 2011
    b>Vascular endothelial growth factors (VEGFs) are critical regulators of vascular and lymphatic function during development, in health and in disease. There are five mammalian VEGF ligands and three VEGF receptor tyrosine kinases...
  20. pmc Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
    J A Forsythe
    Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, USA
    Mol Cell Biol 16:4604-13. 1996
    ..VEGF mRNA was not induced by hypoxia in mutant cells that do not express the HIF-1beta (ARNT) subunit. These findings implicate HIF-1 in the activation of VEGF transcription in hypoxic cells...
  21. ncbi Regulation of vascular permeability by vascular endothelial growth factors
    D O Bates
    Microvascular Research Laboratories, Department of Physiology, Preclinical Veterinary School, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK
    Vascul Pharmacol 39:225-37. 2002
    ..This review will outline the mechanisms by which VEGFs do this and discuss some of the difficulties in interpreting data from VEGF studies due to the conflicting and synergistic effects of these actions...
  22. ncbi Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nat Med 5:495-502. 1999
  23. ncbi Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema
    R J Kaner
    Division of Pulmonary and Critical Care Medicine and Weill Medical College of Cornell University, New York, New York, USA
    Am J Respir Cell Mol Biol 22:657-64. 2000
    ..Together, these data suggest that overexpression of VEGF in the lung may be one mechanism of increased pulmonary vascular permeability in the early stages of acute lung injury...
  24. ncbi The biology of vascular endothelial growth factors
    Tuomas Tammela
    Molecular Cancer Biology Laboratory and Ludwig Institute for Cancer Research, University of Helsinki, 00014 Helsinki, Finland
    Cardiovasc Res 65:550-63. 2005
    ..In this review, we will discuss recent advances in angiogenesis research and provide an overview of the molecular players involved in lymphangiogenesis...
  25. ncbi Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 20:4368-80. 2002
    ..It may also become an important target for cancer therapy...
  26. ncbi Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
    S Soker
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cell 92:735-45. 1998
    ..We propose that neuropilin-1 is a novel VEGF receptor that modulates VEGF binding to KDR and subsequent bioactivity and therefore may regulate VEGF-induced angiogenesis...
  27. ncbi Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation
    M M Deckers
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
    Endocrinology 141:1667-74. 2000
    ..The expression pattern of VEGFs and their receptors shown here suggests that VEGFs play an important role in the regulation of bone remodeling by attracting endothelial cells and osteoclasts and by stimulating osteoblast differentiation...
  28. ncbi Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
    L E Smith
    Department of Ophthalmology, Harvard Medical School and Children s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA
    Nat Med 5:1390-5. 1999
    ..They also explain why diabetic retinopathy initially increases with the onset of insulin treatment. IGF-1 levels, low in untreated diabetes, rise with insulin therapy, permitting VEGF-induced retinopathy...
  29. ncbi Vascular endothelial growth factor (VEGF) and its receptors
    G Neufeld
    Department of Biology, Technion, Israel Institute of Technology, Technion City, Haifa 32000, Israel
    FASEB J 13:9-22. 1999
    ....
  30. ncbi The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences
    D T Shima
    Program in Biological and Biomedical Sciences and the Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 271:3877-83. 1996
    ..These data and reagents will allow the molecular and genetic analysis of mechanisms that control the developmental and pathological expression of VEGF...
  31. pmc VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm
    Lynda Erskine
    School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB25 2ZD, UK
    Neuron 70:951-65. 2011
    ..These findings have identified a permissive midline signal for axons at the chiasm midline and provide in vivo evidence that VEGF-A is an essential axon guidance cue...
  32. ncbi Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
    G H Fong
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Nature 376:66-70. 1995
    ..We suggest that the Flt-1 signalling pathway may regulate normal endothelial cell-cell or cell-matrix interactions during vascular development...
  33. ncbi Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival
    S Ugurel
    Department of Dermatology, Saarland University Hospital, Homburg/Saar, Germany
    J Clin Oncol 19:577-83. 2001
    ..CONCLUSION: Our data suggest that the angiogenic serum factors VEGF, bFGF, and IL-8 are useful predictive markers for overall and progression-free survival in melanoma patients...
  34. ncbi The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA
    K A Houck
    Department of Molecular Biology, Genetech, Inc, South San Francisco, California 94080
    Mol Endocrinol 5:1806-14. 1991
    ..Thus, alternative splicing of VEGF RNA can produce four polypeptides with strikingly different secretion patterns, which suggests multiple physiological roles for this family of proteins...
  35. ncbi Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
    Aernout Luttun
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Nat Med 8:831-40. 2002
    ..Thus, PlGF and Flt1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation...
  36. ncbi Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine
    Seppo Yla-Herttuala
    Department of Biotechnology and Molecular Medicine, A I Virtanen Institute, Kuopio University, Kuopio, Finland
    J Am Coll Cardiol 49:1015-26. 2007
    ..Here, we review the biology and effects of VEGFs as well as the current status of clinical applications and future perspectives of the therapeutic use of VEGFs in cardiovascular medicine...
  37. ncbi The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer
    B K Linderholm
    Department of Oncology, Radiumhemmet, Karolinska Institute and Hospital, Stockholm, Sweden
    Cancer Res 61:2256-60. 2001
    ..4 and 2.1 for BCCS and RFS, respectively. VEGF expression is related to p53 status in human breast cancer patients. Combining VEGF with p53 status resulted in better prognostic prediction...
  38. ncbi Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
    D I Gabrilovich
    Department of Medicine and The Vanderbilt Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6838, USA
    Clin Cancer Res 5:2963-70. 1999
    ..This effect was associated with the induction of significant anti-p53 CTL responses only in this group of mice. These data suggest that inhibition of VEGF may be a valuable adjuvant in the immunotherapy of cancer...
  39. pmc The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
    P Manders
    Department of Medical Oncology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Cancer 87:772-8. 2002
    ..This implies that vascular endothelial growth factor is related with the natural course of breast cancer progression...
  40. ncbi Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
    N W Gale
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York 10591 6707, USA
    Genes Dev 13:1055-66. 1999
  41. ncbi Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis
    G Christofori
    Department of Biochemistry and Biophysics, University of California, San Francisco 94143 0534, USA
    Mol Endocrinol 9:1760-70. 1995
    ..While VEGF may also play an important role in the growth of new blood vessels during islet cell tumorigenesis, it cannot be the only factor required for the activation of tumor angiogenesis...
  42. ncbi Vascular endothelial growth factors and angiogenesis in eye disease
    A N Witmer
    Ocular Angiogenesis Group, Department of Ophthalmology, University of Amsterdam, Amsterdam, The Netherlands
    Prog Retin Eye Res 22:1-29. 2003
    ..On the other hand, this paracrine relation and other physiological functions of VEGFs may be endangered by therapeutic VEGF inhibition, as is currently used in several clinical trials in DR and AMD...
  43. ncbi Development of endothelial cell lines from embryonic stem cells: A tool for studying genetically manipulated endothelial cells in vitro
    G Balconi
    Istituto di Ricerche Farmacologiche Mario Negri G B, R S, E D, Milan, Italy
    Arterioscler Thromb Vasc Biol 20:1443-51. 2000
    ..We propose that this approach may be useful for obtaining endothelial cells carrying gene mutations that are lethal at very early stages of development...
  44. ncbi Vascular endothelial growth factor and vascular targeting of solid tumors
    R A Brekken
    The Hope Heart Institute, Department of Vascular Biology, Seattle, WA 98104 2046, USA
    Anticancer Res 21:4221-9. 2001
    ..We conclude that 2C3 might have dual activity as an anti-angiogenic agent by inhibiting VEGFR2 activity and as a vascular targeting agent for selective drug delivery to tumor vessels...
  45. ncbi VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding
    Shay Soker
    Department of Urology, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Cell Biochem 85:357-68. 2002
    ..These complexes are formed on the surface of EC and in a juxtacrine manner via association of tumor cell NRP1 and EC KDR...
  46. pmc Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo
    Kunlin Jin
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Proc Natl Acad Sci U S A 99:11946-50. 2002
    ..Cells labeled with BrdUrd after VEGF treatment in vivo include immature and mature neurons, astroglia, and endothelial cells. These findings implicate the angiogenesis factor VEGF in neurogenesis as well...
  47. ncbi Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression
    L Hlatky
    Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts 02115
    Cancer Res 54:6083-6. 1994
    ..Thus, mammary stromal cells, only recently considered in the regulation of breast carcinomas, may play a hitherto unrealized role in breast cancer angiogenesis...
  48. pmc Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
    R L Kendall
    Department of Biochemistry, Merck Research Laboratories, Rahway, NJ 07065
    Proc Natl Acad Sci U S A 90:10705-9. 1993
    ....
  49. ncbi The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts
    T Takahashi
    Department of Genetics, Institute of Medical Science, University of Tokyo, Minato ku, Japan
    Oncogene 14:2079-89. 1997
    ..These results suggest that the KDR/Flk-1 utilizes cell type-specific signal transduction pathway(s) for MAP kinase activation and the mitotic response in endothelial cells...
  50. ncbi Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival
    A Obermair
    Department of Gynecology and Obstetrics University Hospital of Vienna, Austria
    Int J Cancer 74:455-8. 1997
    ....
  51. ncbi Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer
    C M Lennard
    Departments of Otolaryngology, Clinical Investigation and Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA
    Surgery 129:552-8. 2001
    ..007). CONCLUSIONS: These data demonstrate that the immunohistochemical pattern of VEGF staining in the initial surgical specimen is strongly associated with the incidence of local and distant metastasis in papillary thyroid cancer...
  52. pmc Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology
    R E Banks
    ICRF Cancer Medicine Research Unit, St James s University Hospital, Leeds UK
    Br J Cancer 77:956-64. 1998
    ..e.g. wound healing, and in tumour metastasis, when platelets adhering to circulating tumour cells may release VEGF at points of adhesion to endothelium, leading to hyperpermeability and extravasation of cells...
  53. pmc Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148
    Maria Grazia Lampugnani
    FIRC Institute of Molecular Oncology, 20139 Milan, Italy
    J Cell Biol 161:793-804. 2003
    ..In sparse cells or in VE-cadherin-null cells, this phenomenon cannot occur and the receptor is fully activated by the growth factor...
  54. ncbi Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth
    H E Ryan
    Department of Biology, University of California, San Diego 92093 0366, USA
    Cancer Res 60:4010-5. 2000
    ..The evidence from these experiments indicates that hypoxic response via HIF-1alpha is an important positive factor in solid tumor growth and that HIF-1alpha affects tumor expansion in ways unrelated to its regulation of VEGF expression...
  55. pmc The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease
    G P Pidgeon
    Royal College of Surgeons in Ireland, Department of Surgery, Beaumont Hospital, Dublin, Ireland
    Br J Cancer 81:1311-7. 1999
    ..These data indicate that endotoxin introduced during surgery is associated with the enhanced growth of metastases following surgical trauma, by altering the critical balances governing cellular growth and angiogenesis...
  56. pmc VEGF-Trap: a VEGF blocker with potent antitumor effects
    Jocelyn Holash
    Regeneron Pharmaceuticals, Incorporated, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Proc Natl Acad Sci U S A 99:11393-8. 2002
    ..VEGF-Trap-mediated blockade may be superior to that achieved by other agents, such as monoclonal antibodies targeted against the VEGF receptor...
  57. ncbi Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis
    M Kaya
    Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan
    Clin Cancer Res 6:572-7. 2000
    ....
  58. ncbi Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
    C Suri
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York 10591, USA
    Cell 87:1171-80. 1996
    ..Angiopoietin-1 seems to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme...
  59. ncbi Vascular endothelial growth factor is a secreted angiogenic mitogen
    D W Leung
    Department of Molecular Biology, Genetech, South San Francisco, CA 94080
    Science 246:1306-9. 1989
    ..Human 293 cells transfected with an expression vector containing a bovine or human VEGF cDNA insert secrete an endothelial cell mitogen that behaves like native VEGF...
  60. ncbi SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    Anne Marie O'Farrell
    Preclinical Research and Exploratory Development, SUGEN, South San Francisco, CA 94080, USA
    Blood 101:3597-605. 2003
    ..These results suggest that further exploration of SU11248 activity in AML patients is warranted...
  61. ncbi Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation
    Helen Hutchings
    GDR CNRS 1927 Angiogenese and UMR CNRS 5089, Institut de Pharmacologie et Biologie Structurale, Toulouse, France
    FASEB J 17:1520-2. 2003
    ..We have thus determined a new VEGF receptor-independent role for immobilized VEGF in supporting cell adhesion and survival through interactions with integrins...
  62. ncbi ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    Stephen R Wedge
    Department of Cancer and Infection Research, AstraZeneca, Cheshire SK10 4TG, United Kingdom
    Cancer Res 62:4645-55. 2002
    ..4 cm(3) volume. ZD6474 is currently in Phase I clinical development as a once-daily oral therapy in patients with advanced cancer...
  63. ncbi Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion
    Shelley R Boyd
    Moorfields Eye Hospital, City Road, London EC1V 2PD, England
    Arch Ophthalmol 120:1644-50. 2002
    ..To establish a role for vascular endothelial growth factor (VEGF) during the onset and clinical course of neovascularization of the iris (NVI) in ischemic central retinal vein occlusion...
  64. ncbi Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
    A Pettersson
    Department of Pathology, Children s Hospital, and Harvard Institute of Human Genetics, Harvard Medical School, Boston, Massachusetts 02215, USA
    Lab Invest 80:99-115. 2000
    ..Finally, the muscular vessels that developed from mother vessels in skin and perimuscle fat have the structure of collaterals and could be useful clinically in the relief of tissue ischemia...
  65. pmc Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4
    J Lee
    Department of Molecular Biology, Genetech, Inc, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 93:1988-92. 1996
    ..A 2.4-kb VRP mRNA is found in several human tissues including adult heart, placenta, ovary, and small intestine and in fetal lung and kidney...
  66. ncbi Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 394:485-90. 1998
    ..As hypoxic stress contributes to many (patho)biological disorders, this new role for HIF-1alpha in hypoxic control of cell growth and death may be of general pathophysiological importance...
  67. ncbi Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival
    Edwin P Hui
    Departments of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Clin Cancer Res 8:2595-604. 2002
    ....
  68. ncbi Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
    P C Maisonpierre
    Regeneron Pharmaceuticals Inc, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Science 277:55-60. 1997
    ..Natural antagonists for vertebrate receptor tyrosine kinases are atypical; thus, the discovery of a negative regulator acting on Tie2 emphasizes the need for exquisite regulation of this angiogenic receptor system...
  69. ncbi Blood vessels and nerves: common signals, pathways and diseases
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Katholieke Universiteit Leuven, Campus Gasthuisberg, Herestraat 49, B 3000, Leuven, Belgium
    Nat Rev Genet 4:710-20. 2003
    ..The realization that both systems use common genetic pathways should not only form links between vascular biology and neuroscience, but also promises to accelerate the discovery of new mechanistic insights and therapeutic opportunities...
  70. ncbi Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease
    Ferdinando Carlo Sasso
    Department of Geriatrics and Metabolic Disease, Second University of Naples, Naples, Italy
    J Am Coll Cardiol 46:827-34. 2005
    ..The aim of the present study was to evaluate the expression and the activity of vascular endothelial growth factor (VEGF) in the hearts of diabetic patients with chronic coronary heart disease (CHD)...
  71. ncbi The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
    B A Keyt
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 271:7788-95. 1996
    ..The present findings indicate that removal of the carboxyl-terminal domain, whether it is due to alternative splicing of mRNA or to proteolysis, is associated with a significant loss in bioactivity...
  72. ncbi VEGF receptor signalling - in control of vascular function
    Anna Karin Olsson
    Department of Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjöldv 20, 751 85 Uppsala, Sweden
    Nat Rev Mol Cell Biol 7:359-71. 2006
    ..Recent insights have shed light onto VEGFR signal transduction and the interplay between different VEGFRs and VEGF co-receptors in development, adult physiology and disease...
  73. ncbi Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species
    Ning Gao
    Mary Babb Randolph Cancer Center, Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, West Virginia 26506 9300, USA
    J Biol Chem 277:31963-71. 2002
    ..These results suggest that the expression of HIF-1 and VEGF induced by vanadate through PI3K/Akt may be an important signaling pathway in the vanadate-induced carcinogenesis, and ROS may play an important role...
  74. ncbi Mesenchymal expression of vascular endothelial growth factors D and A defines vascular patterning in developing lung
    James M Greenberg
    Division of Pulmonary Biology, Children s Hospital Research Foundation, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Dev Dyn 224:144-53. 2002
    ..b>Vascular endothelial growth factors (VEGF) are potent effectors of vascular development...
  75. ncbi Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features
    Stefano La Rosa
    Department of Pathology, Ospedale di Circolo, Varese, Italy
    Hum Pathol 34:18-27. 2003
    ....
  76. ncbi Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803
    X Tian
    Department of Biochemistry and Molecular Biology, Beijing Institute for Cancer Research, Peking University School of Oncology, Beijing, 100034, People s Republic of China
    Biochem Biophys Res Commun 286:505-12. 2001
    ....
  77. ncbi Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer
    Kazuo Shirakawa
    Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan
    Int J Cancer 99:344-51. 2002
    ..These ECs/EPCs incorporated acetylated lipoprotein and were integrated within a HUVEC monolayer in vitro culture on day 5...
  78. pmc Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma
    G H Shen
    Department of Molecular Pathology, Institute of Gerontology, Nippon Medical School, Kawasaki, Japan
    Br J Cancer 83:196-203. 2000
    ....
  79. ncbi Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
    L Yen
    Department of Medicine, Oncology, Lady Davis Institute for Medical Research of the Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec H3T 1E2, Canada
    Oncogene 19:3460-9. 2000
    ..Furthermore, heregulin-mediated angiogenesis is observed in the in vivo CAM assay. This study reports the first evidence of VEGF regulation by heregulin in cancer cells. Oncogene (2000) 19, 3460 - 3469..
  80. ncbi Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts
    E K Rofstad
    Department of Biophysics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo
    Cancer Res 60:4932-8. 2000
    ..Our observations suggest that efficient antiangiogenic treatment of melanoma may require identification and blocking of common functional features of several angiogenic factors...
  81. ncbi Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer
    S Cascinu
    Istituto di Oncologia, Universita degli Studi di Messina, Italy
    Clin Cancer Res 6:2803-7. 2000
    ..66 +/- 0.17; P = 0.0001). VEGF may be used in a clinical setting to identify patients at high risk for relapse who may benefit from adjuvant treatment including new therapeutic strategies such as monoclonal antibody neutralizing VEGF...
  82. pmc Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
    R Ravi
    Johns Hopkins Oncology Center, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 USA
    Genes Dev 14:34-44. 2000
    ..These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis...
  83. ncbi Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
    A Takahashi
    Genetics Division, National Cancer Center Research Institute, Tokyo, Japan
    Cancer Res 54:4233-7. 1994
    ..Biochem. Biophys. Res. Commun., 180: 386-392, 1991). Taken together, these results suggest that VEGF, PIGF, and basic fibroblast growth factor are cooperatively working to increase the angiogenesis in renal cell carcinoma in vivo...
  84. pmc Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells
    G P Pidgeon
    Department of Surgery, Royal College of Surgeons in Ireland, Beaumont Hospital, Beaumont, Dublin 9, Ireland
    Br J Cancer 85:273-8. 2001
    ..Therefore, in addition to its role in angiogenesis and vessel permeability, VEGF acts as a survival factor for tumour cells, inducing Bcl-2 expression and inhibiting tumour cell apoptosis...
  85. ncbi Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway
    Y D Jung
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Angiogenesis 4:155-62. 2001
    ..These data demonstrate that IL-1 beta may induce VEGF in hVSMCs, and suggest that this paracrine signaling pathway, may prevent, in part, apoptosis of ECs...
  86. ncbi Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study
    Yutaka Ogata
    Department of Surgery, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    World J Surg 27:584-9. 2003
    ..Accordingly, VEGF expression in the tumor cells could be a useful prognostic factor for esophageal cancer, particularly in node-positive patients...
  87. ncbi Clinical implications of circulating angiogenic factors in cancer patients
    R T Poon
    Department of Surgery, The University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China
    J Clin Oncol 19:1207-25. 2001
    ..Angiogenesis, a process fundamental to tumor growth, is regulated by angiogenic factors. This article reviews prognostic and other clinical implications of circulating angiogenic factors in cancer patients...
  88. ncbi Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas?
    S Kido
    First Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan
    Eur J Cancer 37:1482-7. 2001
    ..05) than those of patients with tumours displaying low IL-8 and VEGF expression. The results suggest that IL-8 and VEGF may be independent and important prognostic factors in human gastric carcinomas...
  89. ncbi Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development
    D J Dumont
    Division of Molecular and Developmental Biology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Dev Dyn 203:80-92. 1995
    ..These results suggest a possible dual role for VEGF which includes a chemotactic and/or a cellular maintenance role for VEGF during vascularization of the mouse embryo...
  90. ncbi Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line
    T Shimo
    Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, 700-8525, Okayama, Japan
    Cancer Lett 174:57-64. 2001
    ..This is the first evidence that human cancer cells differentially express CTGF protein and mRNA under the control of hypoxic conditions...
  91. ncbi The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium
    Yasuhiro Ikeda
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8582, Japan
    Exp Eye Res 83:1031-40. 2006
    ..These findings suggest the possibility that VEGF-C and VEGF-D expression in RPE modify the ocular angiogenesis as angiogenic stimulators...
  92. ncbi Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121)
    G B Whitaker
    Department of Cardiovascular Research, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Road, Mason, Ohio 45040, USA
    J Biol Chem 276:25520-31. 2001
    ..Taken together, these data suggest a receptor-clustering role for Npn-1, as opposed to Npn-1 behaving as an affinity-converting subunit...
  93. ncbi Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]
    Z Gluzman-Poltorak
    Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel
    J Biol Chem 275:18040-5. 2000
    ..Nevertheless, it is possible that VEGF-induced np-2-mediated signaling will take place only in the presence of other VEGF receptors such as VEGF receptor-1 or VEGF receptor-2...
  94. ncbi Walking the walk: migration and other common themes in blood and vascular development
    David Traver
    Children s Hospital, Howard Hughes Medical Institute, Harvard University Medical School, Boston, MA 02115, USA
    Cell 108:731-4. 2002
    ..Their work suggests that an ancestral function of VEGF was to guide blood cell migration and highlights the conservation of at least one aspect of VEGF signaling during evolution...
  95. ncbi Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1
    D H Kang
    Division of Nephrology, University of Washington, Seattle, WA, USA
    J Am Soc Nephrol 12:1434-47. 2001
    ..The impaired angiogenesis may be mediated by alterations in the renal expression of TSP-1 and VEGF, with the latter being regulated by macrophage-associated cytokines...
  96. pmc In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis
    S Uchida
    Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, Japan
    Br J Cancer 77:1704-9. 1998
    ..0077). We have assumed that VEGF contributes to aggressive characteristics in oesophageal carcinomas and that VEGF expression might be affected by p53 status...
  97. ncbi Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165
    Gakuji Hashimoto
    Department of Pathology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo, Japan
    J Biol Chem 277:36288-95. 2002
    ..MMPs may play a novel role through CTGF degradation in VEGF-induced angiogenesis during embryonic development, tissue maintenance, and/or pathological processes of various diseases...
  98. pmc Host cyclooxygenase-2 modulates carcinoma growth
    C S Williams
    Department of Medicine, The Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2279, USA
    J Clin Invest 105:1589-94. 2000
    ..Additionally, treatment of wild-type mouse fibroblasts with a selective COX-2 inhibitor reduced VEGF production by 92%...
  99. ncbi Vascular permeability factor, an endothelial cell mitogen related to PDGF
    P J Keck
    Department of Cell Culture and Biochemistry, Monsanto Company, St Louis, MO 63167
    Science 246:1309-12. 1989
    ..Clusters of basic amino acids in the COOH-terminal halves of human VPF and PDGF-B are also prevalent. Thus, VPF appears to be related to the PDGF/v-sis family of proteins...
  100. pmc Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells
    R Abu-Ghazaleh
    Department of Medicine, University College London, 5 University Street, London WC1E 6JJ, UK
    Biochem J 360:255-64. 2001
    ....
  101. ncbi Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation
    G Breier
    Max Planck Institut fur Psychiatrie, Martinsried, FRG
    Development 114:521-32. 1992
    ..g. in choroid plexus and in kidney glomeruli. The data are consistent with a role of VEGF as a multifunctional regulator of endothelial cell growth and differentiation...

Research Grants84

  1. Role of a9b1 Integrin in lymphangiogenesis
    Nicholas Vlahakis; Fiscal Year: 2007
    ..This KO8 program will support investigations into the role of alpha9-beta1 integrin and vascular endothelial growth factors (VEGF) C and D in pulmonary lymphatic development and function...
  2. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2007
    ..This work is anticipated to enhance our understanding of KS pathogenesis, provide opportunities for novel therapies for KS, and contribute to the understanding of vascular biology. ..
  3. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2009
    ..This work is anticipated to enhance our understanding of KS pathogenesis, provide opportunities for novel therapies for KS, and contribute to the understanding of vascular biology. ..
  4. Vascular endothelial growth factor induced lung edema
    Robert Kaner; Fiscal Year: 2004
    ..Bronchoalveolar lavage and plasma levels of VEGF will be measured in patients with acute lung injury to develop the hypothesis that overexpression of VEGF in lung may be one mechanism favoring increased permeability. ..
  5. A Novel Model to Study Retinopathy of Prematurity
    David Moscatelli; Fiscal Year: 2003
    ..Our model will provide a useful tool to directly examine the roles of various factors in retinal vascular diseases in a setting that maintains normal tissue architecture. ..
  6. Augmentation of Lymphangiogenesis by Increased Fluid Channeling in Mouse Skin
    Jeremy Goldman; Fiscal Year: 2007
    b>Vascular endothelial growth factors (VEGF)-C and -D have been shown to be necessary for lymphatic proliferation and migration during lymphangiogenesis by binding VEGFR-3 on lymphatic endothelial cells...
  7. VEGFs in tumor lymphatic metastasis
    HAROLD FISHER DVORAK; Fiscal Year: 2010
    ..This application is focused on understanding the mechanisms that these factors use to induce lymphangiogenesis and metastasis in melanoma, as well as how these mechanisms impact emerging cancer therapies. ..
  8. THE MAJOR ANGIOGENIC FACTORS IN PLACENTAL ANGIOGENESIS
    Lawrence Reynolds; Fiscal Year: 2004
    ..Recent studies, including those in gene-knockout mice, indicate that vascular endothelial growth factors (VEGF), fibroblast growth factors (FGF), and angiopoietins (ANG) play major roles in the ..
  9. Integrins and bone matrix in prostate cancer
    Tatiana Byzova; Fiscal Year: 2003
    ....
  10. Integrins and bone matrix in prostate cancer
    Tatiana Byzova; Fiscal Year: 2006
    ..abstract_text> ..
  11. Genetic Control of Cranial Neural Crest Migration
    Hung Hsiang Yu; Fiscal Year: 2005
    ..of neuropilin 2 (Npn-2), a binding receptor for class 3 secreted semaphorin 3C and 3F and vascular endothelial growth factors in vertebrates...
  12. Angiogenesis in Myocardial Ischemia
    Michael Simons; Fiscal Year: 2007
    ..abstract_text> ..
  13. GENETICS OF VEGF MEDIATED ANGIOGENESIS IN MOUSE SKIN
    Bruce J Herron; Fiscal Year: 2010
    ..The Vascular Endothelial Growth Factors (VEGF) are a family of secreted glycoproteins that control angiogenesis...
  14. GENETICS OF VEGF MEDIATED ANGIOGENESIS IN MOUSE SKIN
    Bruce Herron; Fiscal Year: 2009
    ..The Vascular Endothelial Growth Factors (VEGF) are a family of secreted glycoproteins that control angiogenesis...
  15. Angiogenesis:Novel Basic Science Insight & Human Therapy
    Napoleone Ferrara; Fiscal Year: 2004
    ..abstract_text> ..
  16. ANGIOGENIC THERAPY FOR INFARCTED AND ISCHEMIC HEART
    Robert Tomanek; Fiscal Year: 2003
    ..Such interventions have a number of advantages over more invasive interventions, e.g., the delivery of oxogenous growth factors or gene therapy. ..
  17. Regulation of Coronary Vessel Assembly and Growth
    Robert Tomanek; Fiscal Year: 2007
    ..Since cardiac development depends on timely and adequate vascularization, an understanding of coronary vasculogenesis and angiogenesis will provide an important foundation for our understanding of cardiac defects. ..
  18. Skin Manifestations of Tuberous Sclerosis
    Jack Arbiser; Fiscal Year: 2009
    ..Specific Aim 3. To determine whether dysregulation of p16ink4a and PTCH (patched) acts as a modifier of theTS phenotype in transgenic mice expressing dominant negative tuberin. ..
  19. Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy
    Dai Fukumura; Fiscal Year: 2010
    ..This project will advance the basic understanding of NO-mediated vessel maturation and help develop novel strategies to improve the delivery of drugs and oxygen to tumors. ..
  20. NO in Tumor Angiogenesis,Microcirculation & Rad.Therapy
    Dai Fukumura; Fiscal Year: 2006
    ..e. normalization of tumor vessels) to overcome some of the physiological barriers to the delivery of therapeutic agents to solid tumors and introduce a new paradigm to study cell-cell interaction in vivo. ..
  21. Effects of the Angiopoietins on Tie 2 Downregulation
    Christopher Kontos; Fiscal Year: 2005
    ..abstract_text> ..
  22. Role of BMDCs in Solid Tumor Growth and Relapse
    Rakesh Jain; Fiscal Year: 2009
    ..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
  23. Conference on Angiogenesis in Cancer and Other Diseases
    Rakesh Jain; Fiscal Year: 2002
    ..The meeting's synthesis of available information will be particularly thought-provoking for students and post- doctoral fellows. ..
  24. MOLECULAR REGULATION AND ROLE OF PLACENTA GROWTH FACTOR
    Donald Torry; Fiscal Year: 2002
    ..abstract_text> ..